Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vaginitis panel Clear all

Conditions: Vulvovaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more

Conditions: Vaginosis, Bacterial
Interventions: Not listed
Lead sponsor: American International Biotechnology; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis, Vaginal Diseases, Genital Diseases, Female, Female Urogenital Diseases, Urogenital Disease, Candidiasis, Mycoses, Vulvovaginitis, Vulvar Diseases, Vaginosis, Bacterial
Interventions: Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP, Hologic Aptima® BV Assay, Yeast Culture; Diagnostic Test
Lead sponsor: Nanopath, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: North Miami, Florida • New Orleans, Louisiana

Conditions: Vaginitis, Vulvar Diseases
Interventions: Vaginitis panel; Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Trichomonas Vaginalis
Interventions: Point of care tests; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years to 35 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Menopause, Postmenopausal Vaginal Atrophy
Interventions: estradiol, 10 mcg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 51
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 45 more

Conditions: Atrophic Vaginitis, Menopause
Interventions: CO2 fractionated vaginal laser, Estrogens, Conjugated (USP); Device · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Stanford, California • Washington D.C., District of Columbia • Winston-Salem, North Carolina + 3 more

Conditions: Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
Interventions: Vaginal estradiol tablets, Vaginal moisturizer; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Vaginosis, Bacterial
Interventions: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Atrophic Vaginitis
Interventions: IZN-6NVS Cream; Drug
Lead sponsor: Izun Pharma Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: The Bronx, New York • Seattle, Washington

Conditions: Vaginitis
Interventions: BDMax Vaginal Panel; Diagnostic Test
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bacterial Vaginosis, Candida Vaginitis
Interventions: cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP, Hologic Aptima BV Assay; Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 738 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Lakewood, Colorado + 5 more

Conditions: Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause, Lichen Sclerosus, Lichen Planus, Vulvodynia, Endometriosis, Ureaplasma Infections, Cancer, Desquamative Inflammatory Vaginitis
Interventions: Vaginal Swab Collection; Diagnostic Test
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 3,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Fullerton, California • Los Angeles, California • Pasadena, California + 16 more

Conditions: Vaginitis
Interventions: Terazol or oral fluconazole for candidal vaginitis, Metronidazole or Clindamycin for Bacterial Vaginosis, Flagyl for definitively diagnosed vaginal trichomoniasis, Empiric Management; Drug · Other
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method

Large Algorithm Setting and Validation Study

Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions

Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females

Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV

Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers

Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV

Diagnostic Accuracy By Providers Study

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

Vaginal Ecosystem and Network in the United States Study

Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network